Electromed, Inc. — Fiscal 2023 First Quarter Summary
Reporting period: Form 10-Q for the three months ended September 30, 2022, filed November 8, 2022. The filing describes Electromed as a developer, manufacturer, and marketer of High Frequency Chest Wall Oscillation airway-clearance products, principally the SmartVest System. Results are unaudited and should be read with the fiscal 2022 Form 10-K.
Key Financial Metrics
| Metric | Q1 FY2023 | Q1 FY2022 | Change |
|---|---|---|---|
| Net revenue | $10.658 million | $10.001 million | Up 6.6% |
| Gross profit | $8.331 million | $7.701 million | Up 8.2% |
| Gross margin | 78.2% | 77.0% | Up 120 basis points |
| Operating income | $44,000 | $538,000 | Down 91.8% |
| Operating margin | 0.4% | 5.4% | Down approximately 500 basis points |
| Net income | $81,000 | $439,000 | Down 81.5% |
| Basic diluted EPS | $0.01 | $0.05 | Decreased |
| Cash used in operating activities | $(1.694) million | $(576,000) | Greater use of cash |
Revenue Mix
- Home care revenue was $9.632 million, up 3.7%, primarily due to increased referrals and approvals and a larger direct sales force.
- Home care distributor revenue was $554,000, up 255.1%, reflecting increased demand from a primary distribution partner.
- Institutional revenue was $391,000, down 12.9%.
- International revenue was $81,000, down 27.7%.
Balance Sheet, Liquidity, and Capital Structure
- Cash and cash equivalents were $5.998 million at September 30, 2022, compared with $8.153 million at June 30, 2022.
- Working capital was $27.267 million. Accounts receivable were $20.957 million, contract assets were $453,000, and inventory was $3.673 million.
- Total liabilities were $5.990 million and shareholders’ equity was $34.144 million.
- The company had no outstanding borrowings under its $2.5 million revolving credit facility. The full $2.5 million was available at quarter-end, subject to borrowing-base requirements.
- The credit facility expires December 18, 2023, if not renewed, and includes a minimum tangible net worth covenant of $10.125 million and restrictions on additional debt and dividends.
- Investing cash outflows were $256,000, including $241,000 for property and equipment and $15,000 for intangible assets.
- Financing cash outflows were $205,000, including $145,000 for common-stock repurchases and $60,000 for taxes related to net share settlement of option exercises.
Material Changes Versus Prior Comparable Period
- Revenue increased $657,000, but higher selling, general and administrative expense more than offset the gross-profit increase.
- SG&A increased 17.7% to $7.989 million, driven mainly by higher payroll and compensation, expanded sales and support personnel, travel and sales-meeting costs, marketing investment, and professional fees.
- Professional fees included approximately $400,000 of nonrecurring legal compliance costs related to a reimbursement project.
- Research and development expense declined 20.7% to $298,000, primarily due to lower professional-services costs associated with next-generation platform development.
- Operating cash flow deteriorated primarily because of a $1.132 million decrease in accrued compensation, reflecting payment of annual incentives, and increases in inventory, contract assets, prepaid assets, and income-tax receivables.
- Inventory increased $495,000 from June 30, 2022, while contract assets increased $167,000.
- The company repurchased 14,568 shares during the quarter for $145,000. Cumulative repurchases under the authorization totaled 239,195 shares for $2.717 million as of September 30, 2022.
Outlook, Commentary, Risks, and Unusual Items
- Management stated that cash, expected operating cash flows, working capital, and available credit should be adequate for fiscal 2023 and the foreseeable future. No specific revenue or earnings guidance was provided.
- Management expects elevated material and shipping costs to continue during fiscal 2023 because of supply-chain availability and inflationary pressures, which could reduce gross margins.
- A temporary supply-chain interruption affected product availability for certain customers in September 2022. Management did not expect this to affect fiscal 2023 revenue but noted that future disruptions could materially harm operations.
- The CMS waiver that relaxed certain Medicare documentation requirements for respiratory products was extended for an additional 90-day period beginning October 13, 2022. Management stated that the waiver supported Medicare referrals and approvals but identified its potential expiration as a risk.
- COVID-19 effects remain uncertain, including potential impacts on demand, patient access, healthcare programs, manufacturing, supply chains, and operating costs.
- Critical estimates include revenue recognition and variable consideration, inventory valuation, share-based compensation, and warranty reserves. The warranty reserve increased to $1.354 million from $1.256 million at June 30, 2022.
- A putative class action related to a prior data breach was subject to a settlement agreement and proposed court approval. The company stated that ultimate loss exposure could not be determined if the settlement is not approved.
- Management identified reimbursement changes, raw-material shortages, inflation, competition, regulatory compliance, cyberattacks and data breaches, sales-force expansion, international regulation, and credit-facility renewal as significant risks.
- Disclosure controls were assessed as effective, and the company reported no material changes to internal control over financial reporting during the quarter.
Investor Verification Items
- Verify whether the CMS waiver remains in effect and assess the potential effect of expiration on Medicare referrals, approvals, and revenue.
- Monitor gross-margin performance as material, electronic-component, shipping, and labor costs remain elevated.
- Assess whether SG&A investments in sales, reimbursement, and marketing produce sustained revenue growth and operating leverage.
- Review operating cash conversion, inventory growth, contract assets, and the timing of annual incentive payments.
- Confirm the status and financial exposure of the data-breach class-action settlement.
- Track the December 2023 credit-facility expiration, covenant compliance, and availability of the revolving line.
- Evaluate the sustainability of revenue growth given distributor concentration, payer reimbursement estimates, and reliance on government and commercial insurance programs.